2929 N COMMERCE PKWY, MIRAMAR, FL
Financial Statements Restatement - Q1 2026 10-Q Amendment
Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
Other Events
Regained Compliance with Bid Price Rule
Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
Stockholders Elect Class II Directors at HCW Biologics Annual Meeting
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Q2
Amended Quarterly Report
Q1
FY 2025
Q3
Notice of Late Filing for Quarterly Report
S-1
Notice of Exempt Offering of Securities
Amended Registration Statement for Securities
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload